

DRUG QUANTITY MANAGEMENT POLICY – PER DAYS

- POLICY:** Migraine – Other Acute Medications Drug Quantity Management Policy – Per Days
- Nurtec™ ODT (rimegepant orally disintegrating tablet – Biohaven)
 - Reyvow® (lasmiditan tablets – Lilly)
 - Ubrelvy® (ubrogepant tablets – Allergan)

REVIEW DATE: 11/16/2022

OVERVIEW

Nurtec ODT, Reyvow, and Ubrelvy are all indicated for the **acute treatment of migraine** with or without aura in adults.¹⁻³ In addition, Nurtec ODT is also indicated for the preventive treatment of episodic migraine in adults.²

Dosing and Availability

Refer to the Drug Quantity Limits table below for dosing and availability information.

Other Information

Use of acute medications for migraine can potentially lead to medication-overuse headache (generally defined as use for 10 or more days per month for 3 months or more), therefore, they are not intended for regular use.⁴ Guidelines for the management of migraine headache recommend limiting acute (abortive) therapy to less than 2 days per week on a regular basis or 8 treatment days per month. If patients require abortive therapies more frequently, then re-evaluation of the diagnosis and assessment for the use of preventive therapy may be needed.

In general, the quantity limits provided are adequate for two headaches per week for 4 weeks at a maximum FDA-approved dose. Quantities are rounded up to the nearest whole package if needed. The quantity limit is specific to a chemical entity within the same dosage form. Of note, conventional tablets and orally-disintegrating tablets are considered the same dosage form for these purposes.

Policy Statement

This Drug Quantity Management program has been developed to prevent the stockpiling misuse and/or overuse of acute migraine medications. If the Drug Quantity Management rule is not met for the requested medication at the point of service, coverage will be determined by the Criteria below. Approvals are provided for the duration noted below.

Automation: None.

Drug Quantity Limits

Drug Name	Dosing	Availability	Retail Maximum Quantity per 28 Days	Home Delivery Maximum Quantity per 84 Days
Nurtec™ ODT (rimegepant orally disintegrating tablet)	<p><u>Acute migraine treatment:</u> 75 mg (1 tablet) per 24 hours.</p> <p><u>For preventative treatment of episodic migraine:</u> 75 mg (1 tablet) every other day.</p> <p>The safety of using more than 18 doses in a 30-day period has not been established.</p>	75 mg orally-disintegrating tablets Each box contains a blister pack of 8 tablets.	16 tablets (2 boxes)	48 tablets (6 boxes)
Reyvow® (lasmiditan tablet)	<p>Recommended dose is 50 mg, 100 mg, or 200 mg as needed. No more than one dose should be taken in 24 hours. A second dose has not been shown to be effective for the same migraine attack. The maximum dose is 200 mg per 24 hours.</p> <p>The safety of treating an average of more than 4 migraine attacks in a 30-day period has not been established</p>	50 mg tablets Each box contains 8 tablets.	8 tablets (1 box)	24 tablets (3 boxes)
		100 mg tablets Each box contains 8 tablets.	16 tablets (2 boxes)	48 tablets (6 boxes)
Ubrelvy® (ubrogepant tablet)	<p>Recommended dose is 50 mg or 100 mg. If needed, a second dose may be taken ≥ 2 hours after the initial dose. Maximum dose is 200 mg per 24 hours.</p> <p>The safety of treating more than 8 migraines in a 30-day period has not been established.</p>	50 mg tablets Each packet contains 1 tablet and each box contains 10 packets.	20 tablets (2 boxes)	60 tablets (6 boxes)
		100 mg tablets Each packet contains 1 tablet and each box contains 10 packets.	20 tablets (2 boxes)	60 tablets (6 boxes)

CRITERIA

Nurtec ODT

No overrides recommended.

Reyvow 50 mg tablets

No overrides recommended.

Reyvow 100 mg tablets

1. If the strength of the patient’s medication is being increased within the same chemical entity and same dosage form (i.e., from Reyvow 50 mg to 100 mg tablets), approve a one-time quantity override for 8 tablets (1 box) at retail or home delivery.

Ubrelvy 50 mg tablets

No overrides recommended.

Ubrelvy 100 mg tablets

1. If the strength of the patient’s medication is being increased within the same chemical entity and same dosage form (i.e., from Ubrelvy 50 mg to 100 mg tablets), approve a one-time quantity override for 10 tablets (1 box) at retail or home delivery.

REFERENCES

1. Ubrelvy® tablets [prescribing information]. Madison, NJ: Allergan; December 2019.
2. Nurtec ODT [prescribing information]. New Haven, CT: Biohaven; April 2022.
3. Reyvow® tablets [prescribing information]. Indianapolis, IN: Lilly; September 2022.
4. American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. *Headache*. 2019;59:1-18.